Mild or moderate chronic obstructive pulmonary disease
Conditions
Interventions
Three capsules (1 capsule: 30 mg) of high-absorption curcumin capsule (Theracurmin) are orally administered twice daily (after breakfast and dinner, respectively) for 24 weeks.
Three capsules (1 cap
Sponsors
National Hospital Organization Kyoto Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with chronic obstructive pulmonary disease at stage 0, I, or II according to the definition by the Japanese Respiratory Society 2) Patients who have never smoked at least for the past 4 months
Exclusion criteria
Exclusion criteria: 1) severe lung diseases other than COPD 2) renal insufficiency (Cre >= 4.0mg/dL) or hemodialysis 3) severe hepatic disorder or liver cirrhosis 4) Unstable angina pectoris, acute myocardial infarction, severe coronary heart disease (left main trunk or triple vessel disease) 5) Shock, Heart failure, myocardial infarction, Pulmonary embolism 6) Stroke within 3 months 7) Uncontrolled diabetes (more than 10% of HbA1c) 8) Severe infection or trauma 9) Malnutrition 10) Malignancy 11) Anemia (less than 6 mg/dL of Hb) 12) Use of steroid or antibiotics 13) Intake of curcumin 14) Allergy 15) Pregnancy 16) etc
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum levels of inflammatory biomarkers such as IL-6, hsCRP, SAA-LDL | — |
Countries
Japan
Contacts
Public ContactKoji Hasegawa
National Hospital Organization Kyoto Medical Center Division of Translational Research
Outcome results
None listed